Blythe Richard, Ismail Azza, Naqvi Aaizza
The Department of Clinical Neurology, The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, United Kingdom.
The Department of Clinical Neurology, The Royal Hallamshire Hospital, Sheffield Teaching Hospitals, United Kingdom.
J Stroke Cerebrovasc Dis. 2019 Jun;28(6):e75-e76. doi: 10.1016/j.jstrokecerebrovasdis.2019.02.015. Epub 2019 Mar 14.
Intravenous recombinant tissue-plasminogen-activator (rtPA) and mechanical-thrombectomy (MT) are currently the only approved treatments for acute ischemic stroke. Their effectiveness was demonstrated in several clinical trials, and is therefore standard of care. Pregnant women were not included in these studies and consequently the effectiveness and safety in this group are unclear. We present a rare case of a patient in the third-trimester of pregnancy that underwent MT. A 29-year-old woman of 39 weeks' gestation presented with left facial-paresis, hemiparesis, and neglect. Her CT-Angiogram showed a large occlusive thrombus within the right M1-M2 segments. During pregnancy she had developed thrombocytopenia. There was initial treatment decision dilemma. In view of her history of thrombocytopenia, there was concern about administering rtPA due to the risk of bleeding. As the thrombus was large, rtPA may also be ineffective. MT was proposed by the Stroke Physician as the preferred treatment option. A concern from the Interventional-Radiologist was the risk of exposure to radiation and contrast agents. As the patient had a disabling stroke at a young age, decision was made to proceed with MT which started 141 minutes after symptom onset. The clot was aspirated without complications. Final check angiogram showed complete resolution of flow within the right middle cerebral artery territory. The patient underwent elective uncomplicated Caesarean-section 5 days later delivering a healthy new born. Severe stroke in pregnancy is rare, but has grave consequences for both mother and infant. Timely decision-making is crucial. Our case demonstrates that MT can be provided safely and effectively in the third trimester of pregnancy.
静脉注射重组组织型纤溶酶原激活剂(rtPA)和机械取栓术(MT)是目前急性缺血性卒中唯一获批的治疗方法。它们的有效性在多项临床试验中得到了证实,因此是标准治疗方案。这些研究未纳入孕妇,因此该群体中的有效性和安全性尚不清楚。我们报告了一例妊娠晚期接受MT治疗的罕见病例。一名妊娠39周的29岁女性出现左侧面瘫、偏瘫和偏侧忽视。她的CT血管造影显示右侧M1 - M2段有一个大的闭塞性血栓。孕期她出现了血小板减少症。最初存在治疗决策困境。鉴于她有血小板减少症病史,因出血风险而担心使用rtPA。由于血栓较大,rtPA可能也无效。卒中科医生提议将MT作为首选治疗方案。介入放射科医生担心的是辐射和造影剂暴露风险。由于患者年轻且发生了致残性卒中,决定在症状出现141分钟后进行MT治疗。血栓被成功抽吸,无并发症。最终血管造影复查显示右侧大脑中动脉区域血流完全恢复。患者5天后接受了择期无并发症剖宫产,产下一名健康新生儿。妊娠期严重卒中虽罕见,但对母婴均有严重后果。及时决策至关重要。我们的病例表明,在妊娠晚期可以安全有效地进行MT治疗。